DelveInsight’s Hodgkin’s Lymphoma market report provides a comprehensive understanding of the Hodgkin’s Lymphoma, historical and forecasted epidemiology, as well as Hodgkin’s Lymphoma market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan). The report also proffers an analysis of the current Hodgkin’s Lymphoma treatment practice/algorithm, Hodgkin’s Lymphoma market drivers, Hodgkin’s Lymphoma market barriers, and unmet medical needs.
Key Takeaways from the Hodgkin’s Lymphoma Market Report
-
According to the National Organization for Rare Diseases (NORD), most people with the adult form of Hodgkin’s disease are between the ages of 15 and 40 when they are diagnosed.
-
As per the American Cancer Society estimates, there will be 8,830 new cases of Hodgkin Lymphoma in the United States in 2021.
-
Key companies such as ADC Therapeutics, BeiGene, Tessa Therapeutics, and others are expected to enter the Hodgkin’s Lymphoma market.
-
Key emerging Hodgkin’s Lymphoma therapies include ADCT-301, Tislelizumab, Autologous CD30, and others.
-
Camidanlumab Tesirine (ADCT-301) is being developed and evaluated in phase II clinical trial by ADC Therapeutics for the Relapsed/Refractory Hodgkin Lymphoma (R/R HL).
-
Tislelizumab (BGB-A317), developed by BeiGene, is a humanized IgG4 anti-PD-1 monoclonal antibody under investigation that is specifically designed to reduce binding to FcR on macrophages.
Request for the Webex demo of the report @ Hodgkin’s Lymphoma Market Outlook
The Hodgkin’s Lymphoma market report also covers current treatment practices, emerging drugs, Hodgkin’s Lymphoma market share of individual therapies, and current and forecasted Hodgkin’s Lymphoma market Size from 2018 to 2030, segmented by seven major markets.
Hodgkin’s Lymphoma: Overview
Hodgkin’s Lymphoma is a type of lymphoma. Lymphoma is a broad term for cancers that affect the lymphatic system, particularly the lymph nodes. Tumors frequently form in the lymph nodes and the surrounding area. It has been discovered through preliminary research that a variety of factors can cause Hodgkin Lymphoma. These are caused by a contagious agent, such as a virus (e.g., Epstein Barr Virus).
Hodgkin’s Lymphoma Epidemiology Segmentation
The Hodgkin’s Lymphoma report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
-
Hodgkin’s Lymphoma Total Incident Cases
-
Hodgkin’s Lymphoma Age-Specific Incident Cases
-
Hodgkin’s Lymphoma Gender-Specific Incident Cases
-
Relapsed/Refractory Hodgkin’s Lymphoma Incident Population
-
Relapsed/Refractory Hodgkin’s Lymphoma Treatable Cases
Hodgkin’s Lymphoma Treatment Landscape
The main treatment options for Hodgkin’s Lymphoma are Chemotherapy and radiation therapy. Apart from this, some FDA-approved such as Brentuximab vedotin (Adcetris), Rituximab (Rituxan), Nivolumab (Opdivo), and pembrolizumab (Keytruda) are also used to treat Hodgkin’s Lymphoma.
Hodgkin’s Lymphoma Market
The Hodgkin’s Lymphoma market size is anticipated to increase due to the launch of the upcoming therapies such as ADCT-301, Tislelizumab, Autologous CD30, and others by key companies like ADC Therapeutics, BeiGene, Tessa Therapeutics, and others during the forecast period (2021-30).
Get the detailed analysis of the upcoming therapies @ Hodgkin’s Lymphoma Pipeline Therapies
Hodgkin’s Lymphoma Pipeline Therapies and Key Companies
-
ADCT-301: ADC Therapeutics
-
Tislelizumab: BeiGene
-
Autologous CD30: Tessa Therapeutics
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2018-30
Hodgkin’s Lymphoma Key Companies: ADC Therapeutics, BeiGene, Tessa Therapeutics, among others.
Hodgkin’s Lymphoma Key Pipeline Therapies: ADCT-301, Tislelizumab, Autologous CD30, and others.
Hodgkin’s Lymphoma Segmentation: By Geography, By Hodgkin’s Lymphoma therapies
Analysis: Comparative and conjoint analysis of Hodgkin’s Lymphoma emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
|
1. |
Report Introduction |
|
2. |
Hodgkin Lymphoma: Market Overview at a Glance |
|
3. |
Disease Background and Overview: Hodgkin Lymphoma |
|
4. |
Hodgkin Lymphoma Epidemiology and Patient Population (7MM) |
|
5. |
Hodgkin Lymphoma: Country-Wise Epidemiology |
|
6. |
Hodgkin Lymphoma Treatments & Medical Practices |
|
7. |
Hodgkin Lymphoma Marketed Therapies |
|
8. |
Hodgkin Lymphoma Emerging Therapies |
|
9. |
Hodgkin Lymphoma: Market Size |
|
10. |
Hodgkin Lymphoma 7MM: Country-Wise Market Analysis |
|
11. |
Hodgkin Lymphoma United States Market Size |
|
12. |
Hodgkin Lymphoma EU5 Market Size |
|
13. |
Hodgkin Lymphoma Japan Market Size |
|
14. |
Hodgkin Lymphoma Market Drivers |
|
15. |
Hodgkin Lymphoma Market Barriers |
|
16. |
Report Methodology |
|
17. |
DelveInsight Capabilities |
|
18. |
Disclaimer |
|
19. |
About DelveInsight |
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Related Reports
CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market
Get a comprehensive analysis of CAR T-Cell Therapy for Non-Hodgkin Lymphoma pipeline therapies and key companies such as Novartis, Gilead Sciences, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/